Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
Proprietary formulation technology being applied to potentially enhance properties of nimacimab
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye'), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced a formulation development collaboration with Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives. The partnership aims to develop a higher concentration formulation of Skye's CB1 inhibitor, nimacimab, using Arecor's proprietary formulation technology platform, Arestat™.
Skye is evaluating nimacimab, a first-in-class CB1-inhibiting monoclonal antibody, in its Phase 2a CBeyond™ clinical trial in patients with obesity and overweight. Data from the initial 26-week treatment period is anticipated in late Q3 or early Q4 2025.
Under the terms of the agreement, Skye will fund Arecor's development activities with the option to license rights to the new proprietary formulation of nimacimab and associated intellectual property to further develop and commercialize the product.
Sarah Howell, Chief Executive Officer of Arecor, said: 'We are pleased to partner with Skye to support the development of a novel, enhanced formulation of nimacimab, a promising first-in-class candidate with the potential to address significant unmet needs in metabolic disease. This collaboration highlights the strength of our proprietary Arestat™ technology in enabling the development of enhanced therapeutic products that can improve patient outcomes and supports our strategy of bringing innovative medicines to market that address significant unmet patient needs in high-value markets.'
Tu Diep, Chief Operating Officer of Skye, said: 'Approved weight loss drugs have issues with tolerability and adherence, while the small molecule CB1 inhibitors raise concerns about cumulative exposure-related neuropsychiatric toxicities. Nimacimab already has an advantageous pharmacokinetic profile and to date it does not pose these issues. It has a potentially best-in-class half-life of 18–21 days--substantially longer than GLP-1-based therapies--and is being evaluated in a Phase 2a study with once-weekly dosing. Serving our goal of continuous innovation, we are pleased to work with Arecor on the goal of further enhancing nimacimab to improve patient compliance and treatment outcomes.'
About Arecor Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com.
About Skye BioscienceSkye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutic candidates with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
SKYE CONTACTS
Investor Relationsir@skyebioscience.com(858) 410-0266
LifeSci Advisors, Mike Moyermmoyer@lifesciadvisors.com(617) 308-4306
Media InquiriesLifeSci Communications, Michael Fitzhughmfitzhugh@lifescicomms.com(628) 234-3889
ARECOR CONTACTS
Arecor Therapeutics plc
www.arecor.com
Dr Sarah Howell, Chief Executive Officer
Tel: +44 (0) 1223 426060Email: info@arecor.com
David Ellam, Interim Chief Financial Officer
Tel: +44 (0) 1223 426060Email: info@arecor.com
Singer Capital Markets Advisory LLP (NOMAD and Joint Broker)
Phil Davies, Sam Butcher
Tel: +44 (0) 20 7496 3000
WG Partners LLP (Joint Broker)
Nigel Barnes, Satheesh NadarajahDavid Wilson, Claes Spang
Tel: +44 (0) 20 3705 9321
ICR Healthcare
Chris Gardner, David Daley, Lindsey Neville
Tel: +44 (0) 20 3709 5700Email: arecor@icrhealthcare.com
FORWARD LOOKING STATEMENTSThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including 'anticipated,' 'plans,' 'goal,' 'focus,' 'aims,' 'intends,' 'believes,' 'can,' 'could,' 'challenge,' 'predictable,' 'will,' 'would,' 'may' or the negative of these terms or other comparable terminology. These forward looking statements include, but are not limited to statements regarding the pharmacokinetic and pharmacodynamic profile of nimacimab and statements regarding the timing of receipt of final data from Skye's Phase 2 obesity study of nimacimab. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company's periodic filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of Skye's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
an hour ago
- Wall Street Journal
China Tariffs Already Mean Fewer, More Expensive Dolls for American Kids
Carly has auburn hair, blue eyes and stands 18 inches tall. Like most dolls sold in the U.S., she is made in China. That is now a problem for her maker, William Su, who sells tens of thousands of dolls and their accessories a year to Americans through Amazon, Walmart and Target. When President Trump raised tariffs on China to 145% in April, Su, who is based in New York and Taiwan, stopped production because he and his buyers couldn't afford the tariffs.
Car and Driver
an hour ago
- Car and Driver
Airstream's New Trailer Embodies Frank Lloyd Wright's Designs
Airstream has partnered with the Frank Lloyd Wright Foundation for a new limited-edition travel trailer. The Usonian trailer employs many of the design principles found in Wright's architectural masterpieces, such as the Taliesin West property used by Wright as a winter home. The limited-edition camper costs $184,900, and only 200 units will be built. Compared with the multi-level rectilinear look of Fallingwater and the monolithic rotunda of New York's Guggenheim Museum, Frank Lloyd Wright's Taliesin West home in Scottsdale, Arizona, cuts a far subtler silhouette. The property, which served as Wright's winter oasis and is now home to the famed architect's eponymous foundation, consists of a series of low-slung buildings that blend into the surrounding desert. But while Taliesin West lacks the grand presence of some of Wright's other creations, it perfectly encapsulates many of his design philosophies. So, when Airstream—maker of those iconic aluminum campers—decided to partner with the Frank Lloyd Wright Foundation on a new limited-edition trailer, Taliesin West was the ideal inspiration. Airstream Airstream Airstream Airstream Airstream Airstream Airstream Caleb Miller Associate News Editor Caleb Miller began blogging about cars at 13 years old, and he realized his dream of writing for a car magazine after graduating from Carnegie Mellon University and joining the Car and Driver team. He loves quirky and obscure autos, aiming to one day own something bizarre like a Nissan S-Cargo, and is an avid motorsports fan.
Fox News
an hour ago
- Fox News
Former MLB pitcher finds liver donor in high-school classmate he hadn't seen in 20 years
A man's Facebook plea for a liver donor attracted the attention of a high-school acquaintance he hadn't spoken to in 20 years. In April 2024, after experiencing appetite loss and losing 15 pounds in a month, Steven Register, 42, was diagnosed with stage 4 colon cancer, according to SWNS. Doctors told the former MLB pitcher — who played for the Colorado Rockies in 2008 and the Philadelphia Phillies in 2009 — that a liver transplant was likely his best chance of survival. "When we first met with the doctors, they gave me a year to a year-and-a-half to live," Register said, adding that he and his wife, Beth, immediately started researching options. The couple traveled from Auburn, Alabama, to the MD Anderson Cancer Center in Houston, Texas, where Register underwent surgery for a temporary ostomy bag and began chemotherapy, per the SWNS report. Plans for the liver resection were canceled when doctors discovered the tumors were too large, which led the couple to consider a transplant. Register's wife created a Facebook group to search for a living liver donor, hoping someone would come forward in time. Kristin Johnston, a 40-year-old preschool teacher from Roswell, Georgia, saw the post and recognized Register as a former high-school classmate. The two had met in 1999 at Shaw High School in Columbus, Georgia, but hadn't spoken in over two decades, SWNS reported. "It was just so far out of left field," said Register, who couldn't believe it when Johnston volunteered to donate part of her liver. He added, "I haven't seen or talked to her in over 20 years, and for her to reach out like that, it was just meant to be." Johnston said she started by doing a quick online search for live liver donation and discovered that blood type compatibility was the first step. "I just sent him a message," she said. "I said 'hey, what's your blood type?' and he said, 'I'm B positive.'" She responded, "Wait, that's mine too," and offered, "I'll happily donate a lobe if I'm a match." Johnston was later cleared as a match and received the confirmation on a meaningful day. "I got the news on Good Friday, of all days, that I was officially cleared as his liver donor," she said. The surgery, which is expected to take 12 to 14 hours, will involve removing 70% of Johnston's liver and transplanting it into Register, according to SWNS. Both her remaining liver and the donated portion will regenerate over time, giving both a second chance at health. "I got the news on Good Friday, of all days." "For her, she is ultimately giving him the gift of life — for him, a really fresh start in this journey," said Beth Register. Steven Register added, "Hopefully, once I get my liver with all the tumor and cancer out, I'll be cancer-free from there." The Register family — including children McKenzie (16), Blakely (14) and Brooks (8) — launched a fundraiser on SupportNow to help with travel, food and medical expenses. Johnston and her husband Cody, 38, a real estate developer, have three kids of their own — Sawyer (9), Teddy (7) and Dahlia (4). Beth Register said she hopes their family's story raises awareness about the impact of living organ donation. "A lot of people don't realize that live donations, whether it be for livers or kidneys, are even an option," she said. She added that Johnston has been selfless from the start. The families believe fate had a hand in reconnecting them, per SWNS. "We just pray that God is opening all the right doors and that Kristin is the perfect donor for him." "We just pray that God is opening all the right doors and that Kristin is the perfect donor for him," Beth Register said. For more Health articles, visit She continued, "We just appreciate her being willing to put her life on pause to hopefully lengthen his life by many, many, many years."
